224 related articles for article (PubMed ID: 30235247)
21. Assessment of mortality-related risk factors and effective antimicrobial regimens for treatment of bloodstream infections caused by carbapenem-resistant
Zhen S; Zhao Y; Chen Z; Zhang T; Wang J; Jiang E; Zhang F; Mi Y; Zhu X; Han M; Xiao Z; Wang J; Feng S
Front Cell Infect Microbiol; 2023; 13():1156651. PubMed ID: 37415825
[TBL] [Abstract][Full Text] [Related]
22. Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment.
Micek ST; Lloyd AE; Ritchie DJ; Reichley RM; Fraser VJ; Kollef MH
Antimicrob Agents Chemother; 2005 Apr; 49(4):1306-11. PubMed ID: 15793102
[TBL] [Abstract][Full Text] [Related]
23. Empiric combination therapy for gram-negative bacteremia.
Sick AC; Tschudin-Sutter S; Turnbull AE; Weissman SJ; Tamma PD
Pediatrics; 2014 May; 133(5):e1148-55. PubMed ID: 24709936
[TBL] [Abstract][Full Text] [Related]
24. Results from a 13-Year Prospective Cohort Study Show Increased Mortality Associated with Bloodstream Infections Caused by Pseudomonas aeruginosa Compared to Other Bacteria.
Thaden JT; Park LP; Maskarinec SA; Ruffin F; Fowler VG; van Duin D
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28373189
[TBL] [Abstract][Full Text] [Related]
25. Pseudomonas aeruginosa bacteremia: resistance to antibiotics, risk factors, and patient mortality.
Vitkauskienė A; Skrodenienė E; Dambrauskienė A; Macas A; Sakalauskas R
Medicina (Kaunas); 2010; 46(7):490-5. PubMed ID: 20966623
[TBL] [Abstract][Full Text] [Related]
26. Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of the resistance breakpoint.
Tam VH; Gamez EA; Weston JS; Gerard LN; Larocco MT; Caeiro JP; Gentry LO; Garey KW
Clin Infect Dis; 2008 Mar; 46(6):862-7. PubMed ID: 18279040
[TBL] [Abstract][Full Text] [Related]
27. Clinical Predictive Model of Multidrug Resistance in Neutropenic Cancer Patients with Bloodstream Infection Due to Pseudomonas aeruginosa.
Gudiol C; Albasanz-Puig A; Laporte-Amargós J; Pallarès N; Mussetti A; Ruiz-Camps I; Puerta-Alcalde P; Abdala E; Oltolini C; Akova M; Montejo M; Mikulska M; Martín-Dávila P; Herrera F; Gasch O; Drgona L; Paz Morales H; Brunel AS; García E; Isler B; Kern WV; Morales I; Maestro-de la Calle G; Montero M; Kanj SS; Sipahi OR; Calik S; Márquez-Gómez I; Marin JI; Gomes MZR; Hemmatti P; Araos R; Peghin M; Del Pozo JL; Yáñez L; Tilley R; Manzur A; Novo A; Carratalà J;
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015035
[TBL] [Abstract][Full Text] [Related]
28. Risk factors and clinical significance of bacteremia caused by Pseudomonas aeruginosa resistant only to carbapenems.
Lee CH; Su TY; Ye JJ; Hsu PC; Kuo AJ; Chia JH; Lee MH
J Microbiol Immunol Infect; 2017 Oct; 50(5):677-683. PubMed ID: 26188977
[TBL] [Abstract][Full Text] [Related]
29. Risk factors for pan-resistant Pseudomonas aeruginosa bacteremia and the adequacy of antibiotic therapy.
Tuon FF; Gortz LW; Rocha JL
Braz J Infect Dis; 2012; 16(4):351-6. PubMed ID: 22846123
[TBL] [Abstract][Full Text] [Related]
30. Prospective multicenter study of the impact of carbapenem resistance on mortality in Pseudomonas aeruginosa bloodstream infections.
Peña C; Suarez C; Gozalo M; Murillas J; Almirante B; Pomar V; Aguilar M; Granados A; Calbo E; Rodríguez-Baño J; Rodríguez F; Tubau F; Martínez-Martínez L; Oliver A;
Antimicrob Agents Chemother; 2012 Mar; 56(3):1265-72. PubMed ID: 22155832
[TBL] [Abstract][Full Text] [Related]
31. Multidrug-resistant Pseudomonas aeruginosa bloodstream infections: risk factors and mortality.
Tumbarello M; Repetto E; Trecarichi EM; Bernardini C; De Pascale G; Parisini A; Rossi M; Molinari MP; Spanu T; Viscoli C; Cauda R; Bassetti M
Epidemiol Infect; 2011 Nov; 139(11):1740-9. PubMed ID: 21226988
[TBL] [Abstract][Full Text] [Related]
32. Integrating rapid diagnostics and antimicrobial stewardship improves outcomes in patients with antibiotic-resistant Gram-negative bacteremia.
Perez KK; Olsen RJ; Musick WL; Cernoch PL; Davis JR; Peterson LE; Musser JM
J Infect; 2014 Sep; 69(3):216-25. PubMed ID: 24841135
[TBL] [Abstract][Full Text] [Related]
33. Mortality dynamics of Pseudomonas aeruginosa bloodstream infections and the influence of defective OprD on mortality: prospective observational study.
Yoon EJ; Kim D; Lee H; Lee HS; Shin JH; Park YS; Kim YA; Shin JH; Shin KS; Uh Y; Jeong SH
J Antimicrob Chemother; 2019 Sep; 74(9):2774-2783. PubMed ID: 31236593
[TBL] [Abstract][Full Text] [Related]
34. Pseudomonas aeruginosa bacteremia upon hospital admission: risk factors for mortality and influence of inadequate empirical antimicrobial therapy.
Schechner V; Gottesman T; Schwartz O; Korem M; Maor Y; Rahav G; Karplus R; Lazarovitch T; Braun E; Finkelstein R; Lachish T; Wiener-Well Y; Alon D; Chowers M; Bardenstein R; Zimhony O; Paz A; Potasman I; Giladi M; Schwaber MJ; Klarfeld-Lidji S; Hochman M; Marchaim D; Carmeli Y
Diagn Microbiol Infect Dis; 2011 Sep; 71(1):38-45. PubMed ID: 21763093
[TBL] [Abstract][Full Text] [Related]
35. Outcome of bloodstream infections among spinal cord injury patients and impact of multidrug-resistant organisms.
Saliba M; Saadeh D; Bouchand F; Davido B; Duran C; Clair B; Lawrence C; Annane D; Denys P; Salomon J; Bernard L; Dinh A
Spinal Cord; 2017 Feb; 55(2):148-154. PubMed ID: 27995941
[TBL] [Abstract][Full Text] [Related]
36. Effects of an alternative cefepime dosing strategy in pulmonary and bloodstream infections caused by Enterobacter spp, Citrobacter freundii, and Pseudomonas aeruginosa: a single-center, open-label, prospective, observational study.
Deal EN; Micek ST; Reichley RM; Ritchie DJ
Clin Ther; 2009 Feb; 31(2):299-310. PubMed ID: 19302902
[TBL] [Abstract][Full Text] [Related]
37. Pseudomonas aeruginosa bacteremia over a 10-year period: multidrug resistance and outcomes in transplant recipients.
Johnson LE; D'Agata EM; Paterson DL; Clarke L; Qureshi ZA; Potoski BA; Peleg AY
Transpl Infect Dis; 2009 Jun; 11(3):227-34. PubMed ID: 19302282
[TBL] [Abstract][Full Text] [Related]
38. Active monotherapy and combination therapy for extensively drug-resistant Pseudomonas aeruginosa pneumonia.
Khawcharoenporn T; Chuncharunee A; Maluangnon C; Taweesakulvashra T; Tiamsak P
Int J Antimicrob Agents; 2018 Dec; 52(6):828-834. PubMed ID: 30236956
[TBL] [Abstract][Full Text] [Related]
39. Influence of borderline cefepime MIC on the outcome of cefepime-susceptible Pseudomonas aeruginosa bacteremia treated with a maximal cefepime dose: a hospital-based retrospective study.
Su TY; Ye JJ; Yang CC; Huang CT; Chia JH; Lee MH
Ann Clin Microbiol Antimicrob; 2017 Jul; 16(1):52. PubMed ID: 28738848
[TBL] [Abstract][Full Text] [Related]
40. Is fluoroquinolone monotherapy a useful alternative treatment for Pseudomonas aeruginosa bacteraemia?
Wu PF; Lin YT; Wang FD; Yang TC; Fung CP
Infection; 2018 Jun; 46(3):365-373. PubMed ID: 29556979
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]